Navigation Links
Envera Appoints Michael McErlean Fermentation Manager
Date:5/22/2013

West Chester, PA (PRWEB) May 22, 2013

Envera announced today that Michael McErlean has joined the company as Fermentation Manager. Mr. McErlean has an extensive background in cell production and served in a variety of leadership positions throughout his career.

Mike Matheny, President and Owner of Envera stated, “We are very pleased to have Mike join our team”. “Mike’s background is perfectly suited to oversee our newly installed large scale fermentation and downstream processing equipment”, added Matheny. “Mike’s hands on experience optimizing production protocols, establishing preventative maintenance procedures, and troubleshooting equipment is exactly what we need for this stage of Envera’s growth”, concluded Matheny.

Mr. McErlean holds a Bachelor’s Degree from Millersville University. Mike’s professional career includes 18 years of experience divided between Centocor, Merck Sharp & Dohme, and Fibrocell Science. During his time with these companies Mike gained hands on experience running a variety of bioreactors and downstream equipment as well as the implementation of new procedures and processes. Michael was also responsible for the generation of SOP’s, departmental logistics, and Quality/Regulatory issues.

“I am pleased to join a technology based company that is making a difference in the world”, stated McErlean. “Envera’s focus on using naturally occurring microorganisms to replace harsh chemicals, remediate environmental waste, and promote the growth and health of plants and animals was particularly appealing to me”, added Mike. “I am eager to utilize the newly installed fermentation and downstream processing equipment to support Envera’s expanding business”, finished McErlean.

Mr. McE
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Envera Increases Scientific Staff
2. Arecor Appoints Dr. Sarah Howell as Chief Operating Officer
3. Elsevier / MEDai Appoints Tom Zajac as New President
4. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
5. Hybrid Fuels, Inc. Appoints Industry Expert as New CEO
6. BioStorage Technologies Appoints New Member to Board of Directors
7. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
8. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
9. PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO
10. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
11. MAP Pharmaceuticals Appoints W. James OShea to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 2015 Research and ... the "Biopreservation Market by Product, Biospecimen, Application ... report to their offering. The ... 3,731.03 Million by 2020 from USD 2,150.48 Million ... between 2015 and 2020. Biopreservation ensures ...
(Date:9/4/2015)... , ... September 04, 2015 , ... ... product safety and pharmacovigilance services and software tools to pharmaceutical and life sciences ... by Allergan Japan. PRIMO Mobile is a mobile data intake solution that enables ...
(Date:9/3/2015)... ... September 03, 2015 , ... UCLA wide ... ago. Conventional treatment and therapy were not working so Zach decided to undergo ... McKenna treated Zack with precisely guided injections of bone marrow aspirate concentrate (BMAC) ...
(Date:9/3/2015)... AUSTIN, Texas , Sept. 3, 2015  Vermillion, ... focused on gynecologic disease, today announced that Herbert ... owned subsidiary, ASPiRA LABS, is the recipient of the ... Oncology and Biomarkers (ISOBM) for outstanding contributions to the ... receive the award on October 5 th in ...
Breaking Biology Technology:Global Biopreservation Market 2015-2020 - Product, Biospecimen, Application and End User Analysis of the $3.73 Billion Industry 2Global Biopreservation Market 2015-2020 - Product, Biospecimen, Application and End User Analysis of the $3.73 Billion Industry 3November Research Group’s PRIMO Mobile Goes Live at Allergan Japan 2UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute 2UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute 3Vermillion Announces Dr. Herbert Fritsche as Recipient of the 2015 Abbott Award from the International Society of Oncology and Biomarkers 2
... Point of Preventing Bacterial Colonization with ... Leader, VANCOUVER, March 18 /PRNewswire-FirstCall/ - ... ANP), a global specialty pharmaceutical and,medical device ... from its 960,patient clinical trial comparing its ...
... RainDance Technologies, Inc.,a developer of NanoReactor ... Stephen E. Becker as Vice President,Commercial Officer, ... responsible for continuing the growth of the,company,s ... launch of its first,life science offering," said ...
... AAAAI 64th Annual Meeting also show that C1-INH is ... HAE attacks across all body sites, PHILADELPHIA, March ... effective therapy that rapidly relieves acute,abdominal and facial swelling ... serious genetic disorder, according to data,presented today at the ...
Cached Biology Technology:960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 2960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 3960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 4960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 5960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 6960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 7RainDance Appoints Becker Chief Commercial Officer 2RainDance Appoints Becker Chief Commercial Officer 3C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 2C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 3C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 4
(Date:8/5/2015)... ALBANY, New York , August 5, 2015 /PRNewswire/ ... new market report titled "Facial Recognition Market - Global ... - 2022", the global market for facial recognition is ... market is driven by increased demand for surveillance systems ... to the rising number of crimes and terrorist activities ...
(Date:8/4/2015)... -- AMRI (NASDAQ: AMRI ) today reported financial and operating results ... , Second quarter contract revenue of $ 85.2 ... Adjusted contract margins of 26 % , ... decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, with ...
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... redundant portions of the fruit fly genome may not ... from a Princeton-led team of researchers suggest that repeated ... normal development under less-than-ideal growth conditions by making sure ... appropriate times. If similar regions are found in humans, ...
... estimated to afflict as many as 12 million people worldwide ... vulnerable to compounds developed to treat cancer and other disorders, ... have found. Scientists searched the genome of the parasite ... of TOR kinases, proteins that are linked to cell growth ...
... SPOKANE, Wash.Washington State University researchers have discovered a way to ... for slowing and even stopping the growth of tumors. "Hopefully, ... Weihang Chai, an assistant professor in the WSU School of ... "Basically, you make the cancer cell go from immortal to ...
Cached Biology News:Redundant genetic instructions in 'junk DNA' support healthy development 2Redundant genetic instructions in 'junk DNA' support healthy development 3Redundant genetic instructions in 'junk DNA' support healthy development 4Cancer drugs may help stop major parasite 2
...
...
Assay Diluent, 10 L...
... ZMD.474. Immunogen: Synthetic peptide derived ... mouse junctophilin-3. Specificity: Specific for ... protein. Reactivity: Mouse (positive controls: ... and heart tissues). Applications: Western ...
Biology Products: